Rheumatology International

, Volume 39, Issue 10, pp 1697–1702 | Cite as

Incidence of cancer in a cohort of patients with primary Sjögren syndrome in Argentina

  • Martin BromEmail author
  • Sebastian Moyano
  • Ignacio J. Gandino
  • Marina Scolnik
  • Enrique R. Soriano
Cohort Studies


Primary Sjögren syndrome (pSS) is usually a mild disease, but serious complications such as non-Hodgkin lymphoma—and hypothetically other malignancies—may develop. The aim of this study was to evaluate both overall and specific incidence of cancer in a cohort of patients with pSS compared to the expected incidence in general population of Argentina. Retrospective analytic study of pSS patients fulfilling American-European Consensus Group (AECG) criteria, followed from the time of their diagnosis until the end of the study, death, loss of follow- up, or being given a diagnosis of cancer. Cancer incidence for the general population was obtained from GLOBOCAN 2018, and demographic information was obtained from the national institute for statistics and census. Age- and sex-specific Standardized Incidence Ratio (SIR) were then calculated. One hundred fifty-seven patients, with a mean age of 57.8 years (SD 18.3), were included. Mean patient follow-up duration was 7.37 years (SD 4.2), contributing to a total of 1158 patient/years. Fifteen patients developed a malignancy during follow-up. Cancer incidence for pSS patients was compared with the general population’s incidence through SIRs. Female patient’s SIRs for overall cancer was 4.17 (95% CI 2.30–6.87), non-Hodgkin lymphoma 41.40 (95% CI 10.12–102.1), multiple myeloma 41.49 (95% CI 1.14–167.28), tongue cancer 44.4 (95% CI 1.23–177.31), uterus cancer 8.39 (95% CI 0.19–40.73), lung cancer 4.51 (95% CI 0.1–22.16), and breast cancer 3.76 (95% CI 1.04–9.45). An increased overall cancer risk, and particularly for non-Hodgkin lymphoma, multiple myeloma, breast cancer and tongue cancer was observed in female pSS patients compared to control group.


Sjogren’s syndrome [D012859] Hematologic neoplasms [D019337] Lymphoma Non-Hodgkin [D008228] Neoplasms [D009369] 



We thank Dr. Valeria Scaglioni for her participation in the study design, and BS. Rachel V Lyzak for her help in the improvement of the scientific writing of this manuscript.



Compliance with ethical standards

Conflict of interest

Martin Brom declares that he has no conflict of interest. Sebastian Moyano declares that he has no conflict of interest. Ignacio Javier Gandino declares that he has no conflict of interest. Marina Scolnik declares that she has no conflict of interest. Enrique Roberto Soriano reports grants and personal fees from Roche, grants and personal fees from Novartis, grants and personal fees from Abbvie, grants and personal fees from Glaxo, personal fees from Pfizer, personal fees from Lilly, personal fees from Sanofi, personal fees from AMGEN, personal fees from Bristol Myers Squibb, personal fees from Genzyme, outside the submitted work. All listed authors meet the ICMJE 4 criteria for authorship and have approved the final manuscript. All co-authors take full responsibility for the integrity of the study and the final manuscript. This study has been presented in the 2018 PANLAR meeting, abstract #38 (Brom M, Moyano S, Scolnik M, Gandino JI, Soriano ER (2018) Incidence of Cancer in a cohort of patients with primary Sjögren syndrome. Abstracts, 20th PANLAR Meeting. JCR J Clin Rheumatol 24:S1–S174., and in the 2017 ACR meeting, abstract #1483 (Brom M, Moyano S, Scolnik M, Soriano ER (2017) Incidence of Cancer in a Cohort of Patients with Primary Sjögren Syndrome [abstract]. 2017 ACR/ARHP Annual Meeting Abstract Supplement. Arthritis Rheumatol 69:1–4481.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.

IRB approval

IRB00010193, protocol number #5141, Comité de Ética de Protocolos de Investigación del Hospital Italiano de Buenos Aires).

Informed consent

Patients sign a general informed consent on their first visit to our institution, authorizing the use of their medical data in an anonymized way for retrospective studies.


  1. 1.
    Tong L, Koh V, Thong BY-H (2017) Review of autoantigens in Sjogren’s syndrome: an update. J Inflamm Res 10:97–105. CrossRefGoogle Scholar
  2. 2.
    Shahane A, Patel R (2014) The epidemiology of Sjögren’s syndrome. Clin Epidemiol. Google Scholar
  3. 3.
    Fox RI (2005) Sjögren’s syndrome. Lancet 366:321–331. CrossRefGoogle Scholar
  4. 4.
    Leone MC, Alunno A, Cafaro G et al (2017) The clinical spectrum of primary Sjögren’s syndrome: beyond exocrine glands. Reumatismo 69:93–100. CrossRefGoogle Scholar
  5. 5.
    Alunno A, Leone MC, Giacomelli R et al (2018) Lymphoma and lymphomagenesis in primary Sjögren’s syndrome. Front Med 5:1–7. CrossRefGoogle Scholar
  6. 6.
    Yu K-H, Kuo C-F, Huang LH et al (2016) Cancer risk in patients with inflammatory systemic autoimmune rheumatic diseases. Medicine (Baltimore) 95:e3540. CrossRefGoogle Scholar
  7. 7.
    Zhang W, Feng S, Yan S et al (2009) Incidence of malignancy in primary Sjögren’s syndrome in a Chinese cohort. Rheumatology 49:571–577. CrossRefGoogle Scholar
  8. 8.
    Liang Y, Yang Z, Qin B, Zhong R (2014) Primary Sjögren’s syndrome and malignancy risk: a systematic review and meta-analysis. Ann Rheum Dis 73:1151–1156. CrossRefGoogle Scholar
  9. 9.
    Brito-Zerón P, Acar-Denizli N, Zeher M et al (2017) Influence of geolocation and ethnicity on the phenotypic expression of primary Sjögren’s syndrome at diagnosis in 8310 patients: a cross-sectional study from the big data Sjögren Project consortium. Ann Rheum Dis 76:1042–1050. CrossRefGoogle Scholar
  10. 10.
    Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American–European Consensus Group. Ann Rheum Dis 61:554–558. CrossRefGoogle Scholar
  11. 11.
    Global Cancer Observatory, International Agency for Research on Cancer, World Health Organization Cancer Today. Accessed 27 July 2019
  12. 12.
    Instituto Nacional de Estadísticas y Censos Republica Argentina Proyecciones Nacionales. Accessed 27 July 2019
  13. 13.
    Talal N, Bunim JJ (1964) The development of malignant lymphoma in the course of Sjögren’s syndrome. Am J Med 36:529–540. CrossRefGoogle Scholar
  14. 14.
    Theander E, Manthorpe R, Jacobsson LTH (2004) Mortality and causes of death in primary Sjögren’s syndrome: a prospective cohort study. Arthritis Rheum 50:1262–1269. CrossRefGoogle Scholar
  15. 15.
    Schenone L, Pellet A, Mamani M et al (2019) Development of lymphoma in patients with primary Sjögren syndromes. Int J Clin Rheumtol 14:69–74Google Scholar
  16. 16.
    Voulgarelis M, Dafni UG, Isenberg DA, Moutsopoulos HM (1999) Malignant lymphoma in primary Sjögren’s syndrome: a multicenter, retrospective, clinical study by the European concerted action on Sjögren’s syndrome. Arthritis Rheum 42:1765–1772.;2-V CrossRefGoogle Scholar
  17. 17.
    Tomi A-L, Belkhir R, Nocturne G et al (2015) Monoclonal gammopathy and risk of lymphoma and multiple myeloma in patients with primary Sjögren’s syndrome. Arthritis Rheumatol 68:1245–1250. Google Scholar
  18. 18.
    Brito-Zerón P, Kostov B, Fraile G et al (2017) Characterization and risk estimate of cancer in patients with primary Sjögren syndrome. J Hematol Oncol 10:90. CrossRefGoogle Scholar
  19. 19.
    Lazarus MN, Robinson D, Mak V, Moller H, Isenberg D (2006) Incidence of cancer in a cohort of patients with primary Sjogren’s syndrome. Rheumatology 45:1012–1015. CrossRefGoogle Scholar
  20. 20.
    Manzo C, Kechida M (2017) Is Primary Sjögren’s syndrome a risk factor for malignancies different from lymphomas? What does the literature highlight about it? Reumatologia 55:136–139. CrossRefGoogle Scholar
  21. 21.
    Pego-Reigosa JM, Restrepo Vélez J, Baldini C, Fernández R-F, de Larrinoa Í (2019) Comorbidities (excluding lymphoma) in Sjögren’s syndrome. Rheumatology. Google Scholar
  22. 22.
    Giat E, Ehrenfeld M, Shoenfeld Y (2017) Cancer and autoimmune diseases. Autoimmun Rev 16:1049–1057. CrossRefGoogle Scholar
  23. 23.
    Rosa JE, Soriano ER, Narvaez-Ponce L et al (2011) Incidence and prevalence of systemic sclerosis in a healthcare plan in Buenos Aires. J Clin Rheumatol 17:59–63. CrossRefGoogle Scholar
  24. 24.
    Retamozo S, Brito-Zerón P, Ramos-Casals M (2019) Prognostic markers of lymphoma development in primary Sjögren syndrome. Lupus 28:923–936. CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Rheumatology Section, Internal Medicine ServiceHospital Italiano de Buenos AiresBuenos AiresArgentina
  2. 2.University Institute Hospital Italiano de Buenos AiresBuenos AiresArgentina

Personalised recommendations